Lexaria Launches Groundbreaking GLP-1 Study with New Tablet Tech

Lexaria Bioscience Corp. (Nasdaq: LEXX), a global innovator in drug delivery platforms, has announced a significant advancement in its pharmaceutical research by engaging a contract research organization (CRO) to execute Human Pilot Study #7 (GLP-1-H26-7). This groundbreaking study will evaluate two oral DehydraTECH-semaglutide (DHT-sema) compositions against commercially available Wegovy® tablets, marking a pivotal moment in the development of next-generation GLP-1 treatments. The study, which has already seen contracts signed and is awaiting ethics approval, employs a 5-week parallel group design to assess safety, tolerability, and pharmacokinetic properties under fasted conditions. Lexaria aims to build upon previous successes, such as GLP-1-H25-4, by preserving superior safety profiles while potentially matching or exceeding the performance of established oral tablet brands like Rybelsus® and Wegovy®. If successful, the results could attract pharmaceutical partners interested in leveraging Lexaria's proprietary DehydraTECH technology, which enhances drug absorption and reduces side effects through oral delivery.

What sets this study apart are two key innovations: first, Lexaria is introducing an oral tablet DHT-sema composition for the first time, mimicking the delivery modality of Novo Nordisk's Rybelsus® and Wegovy® tablets to optimize absorption. Second, both the tablet and capsule formulations will incorporate salcaprozate sodium (SNAC), evaluated over a multi-dose, multi-week period to reach a steady-state concentration—a critical milestone for assessing long-term efficacy. This contrasts with earlier single-dose studies, such as those referenced in previous Lexaria GLP-1 studies, and aligns with industry standards, as SNAC is also used in Novo Nordisk's products. The study's 5-week duration is designed to provide robust data on sustained drug performance, with patient recruitment set to begin upon ethics board approval. Fully funded from existing corporate resources, this initiative underscores Lexaria's commitment to advancing its DehydraTECH platform, which boasts 65 granted patents and pending applications worldwide, as detailed on their website at www.lexariabioscience.com.

The potential impact of this study extends beyond Lexaria's corporate goals, offering hope for improved treatments in the growing GLP-1 market, which addresses conditions like obesity and type 2 diabetes. By exploring new DehydraTECH enhancements, including tablet formulations and SNAC integration, Lexaria is pushing the boundaries of oral drug delivery, potentially leading to more effective and patient-friendly alternatives to current injectable options. The study's focus on safety and pharmacokinetics could pave the way for commercial partnerships, accelerating the development of innovative therapies. As highlighted in the original release on www.newmediawire.com, this news represents a critical step in Lexaria's journey to revolutionize drug delivery, with implications for healthcare providers, patients, and investors alike, all while adhering to rigorous scientific and regulatory standards.